David Colleran - 09 Mar 2026 Form 4 Insider Report for Anika Therapeutics, Inc. (ANIK)

Role
EVP, General Counsel, Corp Sec
Signature
/s/ David Colleran
Issuer symbol
ANIK
Transactions as of
09 Mar 2026
Net transactions value
$0
Form type
4
Filing time
11 Mar 2026, 16:25:11 UTC
Previous filing
18 Mar 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Colleran David EVP, General Counsel, Corp Sec C/O ANIKA THERAPEUTICS, INC., 32 WIGGINS AVENUE, BEDFORD /s/ David Colleran 11 Mar 2026 0001646558

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ANIK Common Stock Options Exercise +5,465 +11% 55,019 09 Mar 2026 Direct F1, F2
transaction ANIK Common Stock Tax liability -1,919 -3.5% $14.96* 53,100 09 Mar 2026 Direct F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ANIK Restricted Stock Unit Options Exercise -5,465 -100% $0.000000* 0 09 Mar 2026 Common Stock 5,465 Direct F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit ("RSU") represents the contingent right to receive one share of Issuer common stock.
F2 Includes the following shares acquired under the Anika Therapeutics, Inc. Employee Stock Purchase Plan: 800 shares purchased on May 14, 2025 and 800 shares purchased on November 14, 2025.
F3 Reflects an aggregate of 1,919 shares of common stock retained by the Issuer to satisfy tax withholding obligations with respect to RSUs that vested on March 9, 2026.
F4 On March 9, 2023, the Reporting Person was granted 16,395 RSUs vesting in three equal annual installments beginning on March 9, 2024. This transaction reflects the third and final vesting installment of such RSU award.